NNVC NanoViricides, Inc.
$1.02▲ +0.00%
Healthcare
Other
After hours
$1.03▲ +0.98%
Sep 11, 6:59 PM ET
Volume 285.6K
Avg Volume (10D) 358.2K
Key Metrics & Fundamentals
Market Cap
$26.04M
P/E Ratio
–
Div Yield
–%
52W Range
0.85 - 2.23
% vs 50 MA
-27.73%
% vs 200 MA
-19.20%
RSI-14
20.1
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.95
Free Cash Flow
-$1.93M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.86M
COGS
–
Operating Exp
$2.03M
Operating Income
-$2.03M
EBIT
-$2.03M
Pretax Income
-$1.99M
Net Income
-$1.99M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
ACCESS Newswire · Sep 8, 2026 12:30 PM
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
ACCESS Newswire · Aug 31, 2026 12:30 PM
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
ACCESS Newswire · Aug 18, 2026 12:30 PM
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
ACCESS Newswire · Aug 10, 2026 12:30 PM
NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo
MT Newswires · Jul 28, 2026 1:03 PM
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
ACCESS Newswire · Jul 28, 2026 12:30 PM
NanoViricides Shares Fall Pre-Bell After $3.8 Million Direct Stock Sale Pricing
MT Newswires · Jul 24, 2026 12:50 PM
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
ACCESS Newswire · Jul 24, 2026 12:00 PM
NanoViricides Seeks Approval for Phase 2 Trial of NV-387 Oral Gummies to Treat Ebola in Congo
MT Newswires · Jul 22, 2026 1:35 PM
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
ACCESS Newswire · Jul 22, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NNVC's money flow as a full page
Social Sentiment
Avg +0.77 · 3 posts
DDNewsDiscussionTradeNNVC – 5 Key Reasons This Antiviral Microcap Deserves a Look 🧬
r/StockMarket · Sep 12, 2025
The post presents several positive aspects of NNVC, including its technology, pipeline, and market opportunities.
positive
+0.80
DDNewsNNVC – 5 Key Reasons This Antiviral Microcap Deserves a Look 🧬
r/investing · Sep 12, 2025
The post presents several positive factors regarding NNVC, including a proprietary platform and pipeline catalysts. The tone leans towards investment opportunity.
positive
+0.70
TradeDiscussionWent all in on NNVC
r/wallstreetbets · Mar 9, 2025
The author states "Went all in on NNVC," indicating a bullish sentiment.
positive
+0.80
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.